Procter & Gamble (Health & Beauty Care) Ltd.

The Heights, Brooklands, Weybridge, Surrey, KT13 0XP, UK
Telephone: +44 (0)191 297 5000
Fax: +44 (0)191 297 6295
WWW: http://www.uk.pg.com
Customer Care direct line: +44 (0) 8000 850367 (UK)
Customer Care direct line: +353 (1) 800 509 301 (Ireland)


Summary of Product Characteristics last updated on the eMC: 26/10/2007
SPC Vicks Cough Lozenges with Honey


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

VICKS COUGH LOZENGES WITH HONEY


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

ACTIVE INGREDIENT

%

MG/LOZENGE

REFERENCE STANDARD

DEXTROMETHORPHAN

 

0.204

7.33

USP


Go to top of the page
3. PHARMACEUTICAL FORM

LOZENGE FOR ORAL ADMINISTRATION.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

COUGH SUPPRESSANT FOR THE RELIEF OF DRY, IRRITANT COUGH ASSOCIATED WITH COMMON COLD AND INFLUENZA.


Go to top of the page
4.2 Posology and method of administration

ADULTS AND CHILDREN OVER 12;

2 LOZENGES DISSOLVED IN THE MOUTH CONSECUTIVELY. REPEAT EVERY 6 HOURS AS NEEDED. NO MORE THAN 8 LOZENGES PER DAY.


Go to top of the page
4.3 Contraindications

KNOWN HYPERSENSITIVITY TO DEXTROMETHORPHAN OR TO ANY INGREDIENT OF THE LOZENGE.

PATIENTS SUFFERING FROM SEVERE LIVER DISEASE.

PATIENTS RECEIVING MONOAMINE OXIDASE INHIBITOR THERAPY OR WHO HAVE TAKEN A MONOAMINE OXIDASE INHIBITOR WITHIN THE LAST TWO WEEKS

PATIENTS WITH A PRODUCTIVE COUGH


Go to top of the page
4.4 Special warnings and precautions for use

PATIENTS SUFFERING FROM ASTHMA, LIVER DISEASE OR IMPAIRED RESPIRATORY FUNCTION SHOULD CONSULT THEIR DOCTOR BEFORE TAKING THIS PRODUCT.

DO NOT ADMINISTER TO CHILDREN UNDER 12 YEARS.

IF SYMPTOMS PERSIST CONSULT YOUR DOCTOR..

DO NOT EXCEED THE STATED DOSE.

KEEP OUT OF REACH OF CHILDREN.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

SEE SECTION 4.3 REGARDING MAOI THERAPY.


Go to top of the page
4.6 Pregnancy and lactation

THERE IS NO LITERATURE EVIDENCE OF HAZARD DUE TO DEXTROMETHORPHAN BUT USE IS NOT RECOMMENDED DURING THE FIRST TRIMESTER AND DURING BREAST FEEDING.


Go to top of the page
4.7 Effects on ability to drive and use machines

PATIENTS SUFFERING FROM THE UNDESIRABLE EFFECTS OF DIZZINESS, EXCITATION OR MENTAL CONFUSION (SEE SECTION 4.8) SHOULD NOT DRIVE OR OPERATE MACHINERY.


Go to top of the page
4.8 Undesirable effects

REACTIONS ARE UNCOMMON, BUT MAY INCLUDE DIZZINESS, EXCITATION, MENTAL CONFUSION AND GASTROINTESTINAL DISTURBANCES.


Go to top of the page
4.9 Overdose

SYMPTOMS

MILD TO MODERATE OVERDOSAGE MAY CAUSE DIZZINESS, EXCITATION, MENTAL CONFUSION AND GASTROINTESTINAL DISTURBANCES. VERY HIGH DOSES MAY PRODUCE RESPIRATORY DEPRESSION.

TREATMENT OF OVERDOSE

GASTRIC LAVAGE AND GENERAL SUPPORTIVE MEASURES.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

DEXTROMETHORPHAN IS A NON-OPIOID DEXTRO-ISOMER OF MORPHINE. THE DRUG'S COUGH SUPPRESSANT ACTION IS MEDIATED BY A CENTRAL ACTION ON THE COUGH CENTRE IN THE MEDULLA OBLONGATA OF THE BRAIN, RAISING THE THRESHOLD FOR COUGHING.


Go to top of the page
5.2 Pharmacokinetic properties

DEXTROMETHORPHAN BASE IS WELL ABSORBED FROM THE GASTROINTESTINAL TRACT, BUT THERE IS EXTENSIVE FIRST-PASS METABOLISM. METABOLISM OCCURS IN THE LIVER BY DEMETHYLATION, AND THE DRUG IS EXCRETED IN THE URINE AS UNCHANGED DEXTROMETHORPHAN AND DEMETHYLATED METABOLITES INCLUDING DEXTRORPHAN WHICH HAS SOME COUGH SUPPRESSANT ACTIVITY. THERE IS NO FAECAL ELIMINATION. URINARY EXCRETION IS NEGLIGIBLE. VARIATION IN CAPACITY TO METABOLISE DEXTROMETHORPHAN EXISTS BETWEEN INDIVIDUALS AND THE CLINICAL IMPLICATIONS OF THIS ARE NOT FULLY UNDERSTOOD.


Go to top of the page
5.3 Preclinical safety data

N/A.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

SUCROSE

GLUCOSE SYRUP

LACTIC ACID

CITRIC ACID MONOHYDRATE

POTASSIUM HYDROXIDE

LEVOMENTHOL

HONEY

HONEY FLAVOUR L-134515

EUCALYPTUS OIL

WATER


Go to top of the page
6.2 Incompatibilities

NONE KNOWN.


Go to top of the page
6.3 Shelf life

SHELF LIFE (UNOPENED): 3 YEARS

SHELF LIFE (AFTER OPENING

BLISTER PACK): AS FOR UNOPENED PRODUCT


Go to top of the page
6.4 Special precautions for storage

STORE BELOW 25oC


Go to top of the page
6.5 Nature and contents of container

POLYPROPYLENE BLISTER FOIL, WHITE IN COLOUR, WITH BACKING FOIL (PAPER/ALUMINIUM/POLYPROPYLENE BASED ADHESIVE) CONTAINING 12 LOZENGES.

OR

POLYVINYLCHLORIDE/POLYVINYLIDENE CHLORIDE BLISTER FOIL, WHITE IN COLOUR, WITH BACKING FOIL (PAPER/ALUMINIUM/POLYVINYLIDENE BASED ADHESIVE) CONTAINING 12 LOZENGES.


Go to top of the page
6.6 Special precautions for disposal and other handling

NONE.


Go to top of the page
Administrative Data

Go to top of the page
7. MARKETING AUTHORISATION HOLDER

PROCTER & GAMBLE (HEALTH & BEAUTY CARE) LIMITED

THE HEIGHTS

BROOKLANDS

WEYBRIDGE

SURREY

KT13 0XP

UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 0129/0129


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

N/A


Go to top of the page
10. DATE OF REVISION OF THE TEXT

JUNE 2007



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/20327/SPC/


Active Ingredients/Generics

 
   dextromethorphan hydrobromide